双特异性CS1-BCMA CAR-T细胞在复发或难治性多发性骨髓瘤中具有临床活性
研究构建双特异性CS1-BCMA CAR-T细胞治疗16例复发或难治性多发性骨髓瘤患者,中位随访246天时13例(81%)获得总体反应且微小残留病阴性,6例(38%)达严格完全缓解,6例(38%)发生细胞因子释放综合征(1-2级占31%),未观察到神经毒性。
要点
- 16例RRMM接受CS1-BCMA CAR-T,13例(81%)总体反应且MRD阴性,6例(38%)达sCR。
- 细胞因子释放综合征6例(38%),1-2级占31%,未观察到神经毒性。
- 3例孤立性髓外疾病患者均无反应,4例出现BCMA+和CS1+复发或进展。
核心结论
- CS1-BCMA CAR-T细胞在复发或难治性多发性骨髓瘤患者中具有临床活性且安全性良好。
研究设计与样本
- 研究纳入16例复发或难治性多发性骨髓瘤患者,接受CS1-BCMA CAR-T细胞输注,临床试验注册号NCT04662099。
主要发现
- 中位随访246天,13例(81%)获得总体反应且达微小残留病阴性,6例(38%)达严格完全缓解(sCR)。
- 13例反应者中1年总生存率为72.73%,无进展生存率为56.26%。
- 4例患者维持sCR,中位持续时间为17个月。
- 6例(38%)发生细胞因子释放综合征,其中1-2级占31%;未观察到神经毒性。
- 最常见严重不良事件为血液学毒性:白细胞减少100%、中性粒细胞减少94%、淋巴细胞减少100%、血小板减少31%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) bears heterogeneous cells that poses a challenge for single-target immunotherapies. Here we constructed bispecific CS1-BCMA CAR-T cells aiming to augment BCMA targeting with CS1. Sixteen patients with relapsed or refractory (RR) MM received CS1-BCMA CAR-T infusion. Six patients (38%) had cytokine release syndrome, which was of grade 1-2 in 31%. No neurological toxicities were observed. The most common severe adverse events were hematological, including leukopenia (100%), neutropenia (94%), lymphopenia (100%) and thrombocytopenia (31%). Three patients with solitary extramedullary disease (sEMD) did not respond. At a median follow-up of 246 days, 13 patients (81%) had an overall response and attained minimal residual disease-negativity, and six (38%) reached a stringent complete response (sCR). Among the 13 responders, 1-year overall survival and progression-free survival were 72.73% and 56.26%, respectively. Four patients maintained sCR with a median duration of 17 months. Four patients experienced BCMA+ and CS1+ relapse or progression. One patient responded after anti-BCMA CAR-T treatment failure. Lenalidomide maintenance after CAR-T infusion and the resistance mechanism of sEMD were preliminarily explored in three patients. CAR-T cells persisted at a median of 406 days. Soluble BCMA could serve as an ideal biomarker for efficacy monitoring. CS1-BCMA CAR-T cells were clinically active with good safety profiles in patients with RRMM. Clinical trial registration: This study was registered on ClinicalTrials.gov, number NCT04662099.
引用
- Li C, Xu J, Luo W, et al. Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma. Leukemia. 2023. PMID: 37848634. doi:10.1038/s41375-023-02065-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。